title: Bortezomib therapy in myelofibrosis: a phase II clinical trial.
authors.forename: R A
authors.initials: RA
authors.lastname: Mesa
authors.forename: S
authors.initials: S
authors.lastname: Verstovsek
authors.forename: C
authors.initials: C
authors.lastname: Rivera
authors.forename: A
authors.initials: A
authors.lastname: Pardanani
authors.forename: K
authors.initials: K
authors.lastname: Hussein
authors.forename: T
authors.initials: T
authors.lastname: Lasho
authors.forename: W
authors.initials: W
authors.lastname: Wu
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib